CivoxTM is indicated for the treatment of a wide variety of infections caused by susceptible gram-positive and gram-negative organisms including mixed infections caused by two or more organisms. The extensive tissue penetration of CivoxTM combined with its enhanced antibacterial activity (including anti-pseudomonal activity) enables CivoxTM to be used alone pending sensitivity results or in combination with an aminoglycoside or with beta-lactam antibiotics or with an antibiotic active against anaerobes (metronidazole) where the presence of anaerobes is suspected. CivoxTM is indicated for the reatment of the following infections caused by sensitive bacteria:
1. Respiratory Tract Infections
2. Ear, Nose and Throat Infections
3. Gastrointestinal Tract Infections
4. Intra-abdominal Infections
5. Skin and Soft Tissue Infections
6. Bone and Joint Infections - acute and chronic osteomyelitis, septic arthritis.
7. Urinary Tract Infections
8. Gonorrhoea including urethral, rectal and pharyngeal gonococcal infections
9. Gynaecological Infections
10. Eye infections
11. Severe Systemic Infections. CivoxTM is also indicated for prophylaxis against infection in elective upper-gastrointestinal surgery and endoscopic procedures where there is an increased risk of infection.

Dosage & Administration

The dosage of CivoxTM is determined by the severity and type of infection, the sensitivity of the causative organism(s) and the age, weight, and renal function of the patient. The usual intravenous dose is 100 to 400 mg twice daily.

Infusion Rate
Upper and Lower UTI
100 mg (50 ml)
every 12 hourly

Should be administered by
slow intravenous infusion over
periods of 30-60 minutes

The duration of treatment
depends upon the severity of
infection, clinical response
and bacteriological findings.
The usual duration of
therapy for acute infections
is 5 to 7 days. Generally,
therapy should be continued
for at least 3 days after the
signs and symptoms of the
infection have disappeared.
Lower RTI
200 mg (100 ml)
every 12 hourly

Other Infections
200 mg (100 ml)
every 12 hourly

100 mg (50ml)
as a single dose

Children: Ciprofloxacin is usually not recommended for use in children. However, if the benefits of Ciprofloxacin therapy are considered to outweigh the potential risk, the dosage should be 5-10 mg/kg/day in 2 divided doses, depending on the severity of infection. CivoxTM infusion is compatible with sodium chloride 0.9% solution, Ringer's solution, glucose 5% and 10% solutions, glucose saline and fructose 10% solution. Unless compatibility is proven, the infusion should always be administered separately.


Ciprofloxacin should be used with caution in epileptics and patients with a history of CNS disorders. Infusion of fluid should be immediately discontinued if rigor arises for any reason during the process. Do not use if the solution is cloudy, contains particles or after expiry date. Use in Pregnancy: Reproduction study with Ciprofloxacin did not reveal any evidence of teratogenicity, impairment of fertility or impairment of peri/post-natal development. Use in Lactation: Ciprofloxacin has been shown to cause arthropathy in immature animals. It is secreted in breast milk. So Ciprofloxacin should not be used in pregnant and nursing women.

Related Products

Metonid IV Infusion

Metronidazole 0.5% IV